PGEN
$4.38+3.30%
5/21, 4:52 PMPrecigen: Why I Am More Cautious After The Q1 Beat (Downgrade)
Precigen, Inc. delivered $21.6M in Q1 Papzimeos revenue, aligning with bullish expectations but leaving key launch metrics undisclosed. Management projects cash flow breakeven by year-end, but tight cash, high burn, and future margin compression raise execution risk. Papzimeos momentum is positive, yet a lack of patient-level data and potential for pent-up demand clouds true organic growth visibility.
seekingalpha.comView Stock →